Why Is UNITED THERAPEUTICS (UTHR) Stock Up Today?

Why UTHR stock is up today

United Therapeutics stock surged 12.55% to $541.89 in a single session driven by a favorable court ruling on a key patent. A judge upheld claims 1 and 14 of the company's '327 patent, reinforcing its intellectual property position in the pharmaceutical sector. The ruling was viewed as a meaningful positive by RBC Capital, contributing to the stock's strong intraday performance.

What Happened

The court decision came as a significant development for United Therapeutics, affirming the validity of two core claims in its '327 patent. The ruling also found that Liquidia infringes on these claims, with a final judgment expected within one week. This legal clarity has bolstered investor confidence in the company's ability to protect its innovations and maintain market exclusivity for its products. The stock opened at $482.20 and climbed to a session high of $556.20 at 1:00 PM ET before settling at $542.01. The volume of 1.9 million shares traded so far is 3.4 times the 3-month daily average, indicating heightened interest in the stock.

What The Data Shows

The stock's fundamentals reflect a strong financial position, with a market cap of $20.8B, a P/E ratio of 17.2, and a net margin of 41.6%. Revenue has grown by 2.5% in the trailing twelve months. The stock's beta of 0.56 suggests it is less volatile than the broader market. Over the 52-week period, the stock has traded between $409.07 and $609.35. On September 30, the stock printed 19 fresh 52-week highs and 7 fresh 52-week lows, showing continued momentum. Insider transactions over the last 90 days include 70 sells totaling $330.6M, with no insider purchases reported.

What To Watch

Goldman Sachs recently initiated coverage on United Therapeutics with a Sell rating and a price target of $321. Investors should monitor the final court judgment related to the '327 patent and the company's broader legal and strategic developments.